Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. - Wikidata - wikimedia - TriplyDB

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.

http://www.wikidata.org/entity/Q35185688

about

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.The calcium pump plasma membrane Ca(2+)-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin.Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer Molecular Classification of Triple-Negative Breast Cancer Breast cancer molecular subtypes: from TNBC to QNBC Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.Novel therapeutic strategies in the treatment of triple-negative breast cancer.The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression Mouse mammary stem cells express prognostic markers for triple-negative breast cancer Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.Targeting thyroid hormone receptor beta in triple-negative breast cancer.Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues.Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer.Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.Clinical implications of molecular heterogeneity in triple negative breast cancer.Basal-like breast cancer: molecular profiles, clinical features and survival outcomes miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer Triple-negative breast cancer: treatment challenges and solutions.The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression.PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5.

P2860

Q26747792-3A07946D-9542-453C-8B58-903C1FCC5436 Q26775086-6FC50973-DA62-45A4-8EB5-1F1A43F5C67D Q27311085-27313ABD-B415-4DD3-A07E-42A70A55AB9C Q27317001-0487C5F9-12E1-431B-A06D-9DFF16D3AC5F Q28074613-F7BE7D1E-6FE4-41A6-96BB-84CD9758B510 Q28076661-1E9B8BE4-7EE8-4D6B-8906-0DA21C572A39 Q28076805-C69ACF1F-0EAE-4F05-AB4C-AAE985A1482D Q30491493-AD9CE03B-17C5-47FC-A4AA-F966A09C90D2 Q31138624-78BDEF1C-9989-41EE-A856-5F7BEE73F504 Q33585917-25E6FBB8-0BE7-4692-8856-E69F226C9C1E Q33591876-17BBB6F4-E57A-44B7-ACBB-97F5E211C888 Q33618290-CDC4165F-7FD7-4204-815C-689C93E6558D Q33880064-89615D2C-7988-42B8-8C7F-5375C4BDCFBA Q33887682-FF29515F-E5B9-4475-B4C3-6B1DBD01448D Q33915044-72CDA9B9-9683-4215-84A6-F7580ACD7284 Q33915057-86B8935E-DB40-42FD-BC0D-16AB1013702F Q34476337-48886A90-6A01-448D-B46C-2E2159DC6285 Q34512092-41CBD9CD-1E8B-4FD7-BEE0-6F794A3B65FB Q35214539-972C92D0-22F1-4C29-9F71-B08AFEAC7E3D Q35238287-410D883F-13E7-487A-8C34-67820ECE861A Q35314135-93CE163C-A681-4C26-8F49-991A44648238 Q35564703-F614993B-EDD3-404E-83AE-3525A73DF0FB Q35593154-B4C9D89B-8A89-449D-8784-FFC7A8A5DB25 Q35651216-F0FCB6CB-980F-4052-94A3-62E83D627B51 Q35815004-122149C5-E456-4EAF-AC7F-A35C988EAF2C Q36054418-EC8EC8DB-62F2-492A-8F0C-6FF6DE2C8811 Q36087198-E3169D2A-0B18-4C1B-B0A6-05EF7E3947EA Q36231343-7E126066-36C5-4548-A412-858BD613C1FA Q36271396-8E590878-16A0-49EC-BDC2-1319CE17068B Q36325873-2DE615A3-94EC-42DA-A810-CC973809FC6E Q36586444-2BFC3888-D214-474B-A83E-36FD80D19E3E Q36686920-DB140B6E-EB9D-492B-A5DC-1D4AA8B22FDB Q36844915-099BDB38-609A-4F9B-92A4-83173CA730A6 Q36862936-2B2AF131-13EF-4A8B-93A6-2A71E4D10B6B Q36917747-842B7952-8D9C-4AA7-B307-2780553FFDBE Q36940085-0845EE16-FE98-4EFD-83A1-739A2ECD978D Q37022393-14528DC0-C780-4F98-896F-F6F3324B6BCB Q37026725-D03B971D-04FA-401F-B217-A9905044E942 Q37144576-6933BC94-B078-4609-8718-4E3A43FE500A Q37269350-2E060DDB-1703-4348-994F-B941AB068A39

P2860

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.

http://www.wikidata.org/entity/Q35185688

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Comprehensive genomic analysis ...... triple-negative breast cancer.

@ast

Comprehensive genomic analysis ...... triple-negative breast cancer.

@en

type

label

Comprehensive genomic analysis ...... triple-negative breast cancer.

@ast

Comprehensive genomic analysis ...... triple-negative breast cancer.

@en

prefLabel

Comprehensive genomic analysis ...... triple-negative breast cancer.

@ast

Comprehensive genomic analysis ...... triple-negative breast cancer.

@en

P1433

Q35185688-FB69FFF0-E42A-4BCF-A26A-9F14182062D6

P1476

Q35185688-E7FD9E10-34CB-46CA-9C17-8AC13F0EBB00

P2093

Q35185688-040B2556-0E00-4D91-B4A0-86D867027B15

Q35185688-069DD5FD-7EE8-4D3A-8239-10A55F352C0F

Q35185688-0D00ABCB-748A-4727-8A6F-0D3BA61DD094

Q35185688-304A6489-68FE-48CA-9035-9C7DF82782A4

Q35185688-5309C303-FD6B-424B-AF17-0688103AC256

Q35185688-54AE756B-5390-4012-98E8-4FA59B79686C

Q35185688-61732577-027E-4E18-B27F-B8388D09DAFE

Q35185688-7F0D65E1-B0B2-4062-A753-46C795F2E41B

Q35185688-8332BBFE-08E4-4E82-8311-90C40D96DC9F

Q35185688-97A3387E-A6C9-4642-BEE7-A32A46F8C754

P2860

Q35185688-0B0D4165-7BEF-4231-A727-C7DC18F9FC6C

Q35185688-2232BC7B-471E-42B6-B492-D107D5DA2524

Q35185688-28E857E6-2678-4B65-80B3-272EBB48CAFB

Q35185688-52B0B488-69AE-4183-B641-DCC84A27B219

Q35185688-57722E74-806D-43A9-A5A9-8C4A5F993A74

Q35185688-5B1F16BE-0971-49AB-A259-096C30DDE220

Q35185688-659E6A9C-9686-45BF-9511-711C6B625B5B

Q35185688-67876923-8757-402F-A8CB-9F78B503DDE8

Q35185688-71AFC32B-F4C7-4CBE-B38D-AA473D556020

Q35185688-780C16F8-E133-4527-88FC-66791857A96C

P304

Q35185688-B8A71149-A1F8-4C78-A764-F4D295063DEE

P31

Q35185688-C2A74D4E-C731-4448-8B9F-D61170932BE8

P356

Q35185688-8DC05D0F-9638-47CB-BBAA-17EB1E9CCAEA

P407

Q35185688-BB84B946-BADE-4779-BF4E-4601A257927E

P433

Q35185688-92DBCA9E-72DE-465D-B700-3D77DAA55A45

P478

Q35185688-32958C94-DCBA-4E3B-8D6B-1F57A76EAEE1

P50

Q35185688-DEFC91B1-3581-48DF-8258-4B1C11B006F6

P577

Q35185688-C908EB23-8512-4F32-B3B4-188A414B4ED0

P698

Q35185688-240C85F0-C89E-45D0-AD01-D1BFD5CF3837

P932

Q35185688-DBFD9789-105B-4E5B-9C41-96E7C6453D07

P356

1078-0432.CCR-14-0432

P1433

Clinical Cancer Research

P1476

Comprehensive genomic analysis ...... triple-negative breast cancer.

@en

P2093

Alejandro Contreras

http://www.w3.org/2001/XMLSchema#string

C Kent Osborne

http://www.w3.org/2001/XMLSchema#string

Ching C Lau

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

Graham M Poage

http://www.w3.org/2001/XMLSchema#string

Jenny C Chang

http://www.w3.org/2001/XMLSchema#string

Kyle R Covington

http://www.w3.org/2001/XMLSchema#string

Matthew D Burstein

http://www.w3.org/2001/XMLSchema#string

Michelle I Savage

http://www.w3.org/2001/XMLSchema#string

Powel H Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

affy--analysis of Affymetrix GeneChip data at the probe level

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Supervised risk predictor of breast cancer based on intrinsic subtypes

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Subsystem identification through dimensionality reduction of large-scale gene expression data

P304

1688-1698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-0432

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25208879

http://www.w3.org/2001/XMLSchema#string

P932

4362882

http://www.w3.org/2001/XMLSchema#string